Navigation Links
Pulmo BioTech Inc. Completes Bio-Distribution Studies
Date:7/7/2008

NEW YORK, July 7 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced that its subsidiary, PulmoScience Inc. has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of Molecular Imaging of the vascular system of the lungs.

Molecular Imaging uses a molecule designed to bond specifically to certain parts of the body. In the case of PulmoBind, the chosen molecule was designed to bond only to the inner walls of the vascular system of the lungs. Because the molecule (code named DFH-12) is tagged with a radionuclide, the integrity of the lung's vascular system can then be imaged using the Gamma Cameras which are typically available in all hospitals with a Nuclear Medicine department.

It is important for diagnostic image quality that the PulmoBind molecule is only retained in the lungs, and we are very pleased to announce that in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention (~ 1/10th) in the liver and heart. It is equally important that after imaging the molecule is quickly eliminated from the body and further bio-distribution studies have show that after 240 minutes the majority of the injected molecules have been eliminated through the kidneys and bladder.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was esta
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
2. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
7. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
10. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
11. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... MUNICH , May 22, 2013 JenaValve ... transcatheter aortic valve implantation (TAVI) systems for the treatment of ... the J enaValve Eval U ation of Long Term ... ients with S E vere Ao R tic Stenosis (JUPITER) ... is a post-market registry to evaluate five-year long term safety ...
(Date:5/22/2013)... May 22, 2013  Milliman, Inc., a premier global ... its 2013 Milliman Medical Index (MMI), which measures the ... receiving healthcare benefits through an employer-sponsored preferred provider organization ... family in 2013 is $22,030. "For ... year on a percentage basis was the lowest in ...
(Date:5/22/2013)... May 22, 2013 Z-Medica, a leading developer ... launched the first-ever line of products designed to meet ... includes QuikClot ® EMS 4x4 Dressing, QuikClot ® ... EMS Rolled Gauze™, all custom-designed to help responders stop ... be transported to a hospital or trauma center. The ...
Breaking Medicine Technology:First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 2First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 3First Results Of The JUPITER Registry On Long Term Performance And Safety Of The Transapical JenaValve TAVI System 4Annual Healthcare Cost for a Typical American Family is $22,030 According to 2013 Milliman Medical Index 2Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2
... VIVUS, Inc. (Nasdaq: VVUS ... (TA-303), a phase 3 clinical trial evaluating the safety ... treatment of erectile dysfunction (ED),will be presented this afternoon ... in Washington D.C.  The meeting is jointly sponsored by ...
... (NYSE: WPI ) today announced that its subsidiary, ... Food and Drug Administration (FDA) for Nabumetone Tablets USP, 500 ... shortly. Nabumetone had total U.S. sales of ... according to IMS Health.  Nabumetone is indicated for the relief ...
Cached Medicine Technology:Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 2Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 3Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 4Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 5Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting 6Watson's Nabumetone Tablets Receive FDA Approval 2
(Date:5/22/2013)... York (PRWEB) May 22, 2013 Phelps ... established the Westchester Lung Nodule Center for individuals ... receive lung cancer care. Lung cancer is the deadliest form ... more people in the U.S. die from lung cancer than ... with all cancers, early detection increases survival rates. It ...
(Date:5/22/2013)... 2013 Registered Dietitian and Founder of Tatalou ... Tatalou.com sharing a recipe for making energy bars at home. ... Bars ,” takes a recipe modified from one recently ... “Every day it gets more and more difficult to understand ... “The size of the nutrition label continues to grow and ...
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 HR ... event, hosted at the Gwinnett County Fairgrounds, on Friday ... company before, they far surpassed expectations; raising over $6,300 ... corporate sponsor for the event, donating the first $3,000 ... Beesley , challenged the internal staff to match the ...
(Date:5/22/2013)... May 22, 2013 Go Classy the ... announced the launch of their newest website http://www.Desire-Mexico.com ... of like minds, Desire Resorts have become the premier ... a feeling of total liberation while allowing you to ... COO of Go Classy Tours / Caribbean-Hideaways. He goes ...
(Date:5/22/2013)... News) -- In the aftermath of this week,s deadly tornado, ... for children and relatives, but also their pets. ... disaster and relocating to temporary housing can be stressful, but ... tips on how to ease that transition. One smart ... that can be used to help identify any animals displaced ...
Breaking Medicine News(10 mins):Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2Health News:Simple Steps Can Protect Pets in Weather Disasters 2
... , WEDNESDAY, May 26 (HealthDay News) -- Researchers report that ... the brain in mice -- a finding that could help ... who suffer from Alzheimer,s disease and stroke. , Removing clots ... blood to flow unimpeded, since blockages can lead to a ...
... Complete Genomics Inc., a third-generation human genome sequencing ... member of the Roche Group (SIX: RO, ROG; OTCQX: ... to sequence and compare a patient,s primary lung tumor ... researchers to compare the patient,s genome before and after ...
... are reporting development of a fast, simple, inexpensive method ... may cause skin allergies in people -- a method ... appears in ACS, Chemical Research in Toxicology , ... colleagues note the existence of public sentiment against the ...
... dramatically increased survival in the small group of patients who ... findings will be presented at the annual meeting of the ... June 4-8 in Chicago. Mayo oncologists say this new ... this rare cancer seems to be confined to the neck. ...
... undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning ... possible adverse side effects on oral health, according to a ... the American Dental Association (JADA). , Use of bisphosphonates ... osteonecrosis of the jaw (BON) that occurs spontaneously or after ...
... ... Center has become the first Community of Respect™ Medical Center in the Anti-Defamation ... ... Medical Center has become the first Community of Respect™ Medical Center in the ...
Cached Medicine News:Health News:Brain Cells May Serve as Clot-Busters 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Some bisphosphonates users unfamiliar with drug's possible side effects on oral health 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2
... Oscors proprietary quadripolar pacing wire ... pacing and sensing in the ... two bipolar wires in one ... the atrium and ventricle are ...
... Oscors proprietary quadripolar pacing ... consistent pacing and sensing in ... combining two bipolar wires in ... for the atrium and ventricle ...
... The TME 227 T ... used for temporary cardiac pacing ... open-heart surgery. The TME 227 ... in the myocardium, which allows ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: